Systemic therapy of acne with isotretinoin: Current status;Systemische behandlung der akne mit isotretinoin: Aktueller stand

Hautarzt

Volumn 48, Issue 12, 1997, Pages 881-885

  Plewig, Gerd ^a   Albrecht, Gisela ^b   Henz, Beate M ^c   Meigel, Wilhelm ^d   Schöpf, Erwin ^e   Stadler, Rudolf ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Vivantes Klinikum Spandau   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e UNIVERSITY OF FREIBURG   (Germany)

^f KLINIKUM MINDEN   (Germany)

Author keywords

Acne; Acne therapy; Isotretinoin

Indexed keywords

ISOTRETINOIN;

ACNE; COST BENEFIT ANALYSIS; DRUG INDICATION; HUMAN; REVIEW;

EID: 0031467129     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001050050679     Document Type: Review

References (33)

1. Clark SM, Cunliffe WJ (1995) The use of isotretinoin in the treatment of acne in children. Br J Dermatol 133 [Suppl 45]:39
2. Cunliffe WJ, Gray JA, Macdonald-Hull S, Hughes BR, Calvert RT, Burnside CJ, Simpson NB (1991) Cost effectiveness of isotretinoin. J Dermatol Treatment 1:285-288
3. Cunliffe WJ, Layton AM (1993) Oral isotretinoin: patient selection and management. J Dermatol Treatment 4 [Suppl 2]:10-15
4. Fachinformation Roaccutan® Stand März 1996
5. Goulden V, Layton AM, Cunliffe WJ (1995) Current indications for isotretinoin as a treatment for acne vulgaris. Dermatol 190:284-287
6. Harms M (1992) Aknebehandlung mit systemischem Isotretinoin: Aktuelle Literaturübersicht. Z Hautkr 67:969-972
7. Jansen T, Neubert U, Plewig G (1994) Gramnegative Follikulitis. Münch Med Wochenschr 136:93-96
8. Jansen T, Plewig G (1995) Orale Behandlung der Rosazea mit Isotretinoin. Dtsch Med Wochenschr 120:1745-1747
9. Jones DH, King K, Miller AJ, Cunliffe WJ (1983) A dose-response study of 13-cis-retinoic acid in acne vulgaris. Br J Dermatol 108:333-343
10. Lafarge H, Levy PE (1987) Evaluation économique d'une innovation médicamenteuse: Le traitement de l'acné sévère par Roaccutane. J Economie Med 5:117-127
11. Layton AM (1996) Long-term safety and efficacy of oral isotretinoin in less severe acne. Retinoids Today and Tomorrow 43:6-7
12. Layton AM, Cunliffe WJ (1992) Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 27:52-57
13. Layton AM, Knaggs H, Taylor J, Cunliffe WJ (1993) Isotretinoin for acne vulgaris - 10 years later: a safe and successful treatment. Br J Dermatol 129:292-296
14. Lee ML, Cooper A (1991) Isotretinoin: cost benefit study. Australasian J Dermatol 32:17-20
15. Lefranq H, Walker-Nasir E (1994) Retinoide und Arzneimittel-Interaktionen. Roche Retinoid-Spezial
16. Macdonald-Hull S, Cunliffe WJ (1989) The safety of isotretinoin in patients with acne and systemic diseases. J Dermatol Treatment 1:35-37
17. Macdonald-Hull S, Cunliffe WJ, Hughes BR (1991) Treatment of the depressed and dysmophophobic acne patient. Clin Exp Dermatol 16:210-211
18. Margolis DJ, Attie M, Leyden JJ (1996) Effects of isotretinoin on bone mineralization during routine therapy with isotretinoin for acne vulgaris. Arch Dermatol 32:769-774
19. Marsden JR (1988) Effect of isotretinoin on carbamazepine pharmacokinetics. Br J Dermatol 119:403-404
20. Meigel W, Gollnick H, Wokalek H, Plewig G et al. (1983) Orale Behandlung der Acne conglobata mit 13-cis-Retinsäure. Hautarzt 34:387-397
21. Michaelsson G, Vahlquist A, Mobacken H, Hersle K, Landegren J, Rönnenfält L, Nordin K, Franzen K, Pettersson U (1986) Changes in laboratory variables induced by isotretinoin treatment of acne. Acta Derm Venerol 66:144-148
22. Mills CM, Marks R (1993) Adverse reactions to oral retinoids. Drug Safety 9:280-290
23. Plewig G, Gollnick H, Meigel W, Wokalek H et al. (1981) 13-cis-Retinsäure zur oralen Behandlung der Acne conglobata. Hautarzt 32:634-646
24. Plewig G, Kligman AM (1994) Akne und Rosazea 2. Aufl. Springer, Berlin Heidelberg New York, S 624-653
25. Shalita AR, Cunningham WJ, Leyden JJ, Pochi PE, Strauss JS (1983) Isotretinoin treatment of acne and related disorders: an update. J Am Acad Dermatol 9:629-638
26. Simpson NB (1993) Social and economic aspects of acne and the cost-effectiveness of isotretinoin. J Dermatol Treatment 4 [Suppl 2]:6-9
27. Strauss JS, Rapini RP, Shalita AR (1984) Isotretinoin treatment for acne: results of a multi-center dose-response study. J Am Acad Dermatol 10:490-496
28. Vahlquist A (1992) Long-term safety of retinoid therapy. J Am Acad Dermatol 27:29-33
29. Van Dooren-Greebe RJ, Lemmens JAM, De Boo T, Hangx NMA, Kuijpers ALA, Van de Kerkhof PCM (1996) Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities. Br J Dermatol 134:71-76
30. Vogt HJ, Reiser M, Zumbusch R (1991) Knochenveränderungen unter Isotretinoin-Therapie. Dtsch Dermatol 39:71-76
31. Walters BNJ, Gubbay SS (1981) Tetracycline and benign intracranial hypertension: report of five cases. Br Med J 282:19-20
32. Warren KJ, Cruz PD (1996) Clinical outcome and cost analysis of oral isotretinoin versus conventional regimens in the treatment of moderate acne vulgaris in male patients. Abstract P 12, Am Acad Dermatol, 5th annual meeting, Washington DC, 10-15 February
33. Wishart J, Villiger J (1991) Cost-benefit of isotretinoin (Roacutane). NZ Med J 104:192